An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 24 Oct 2016 Status changed from recruiting to completed.
- 13 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 13 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.